Prometheus Laboratories Inc.

Anne has IBD. She’s been prescribed biologic therapy. Is it the right biologic for her? Soon, Respondr™ will empower you with objective evidence to help you answer that question before she starts therapy. #Gastroenterology #IBD #GI #GIHealth

A new study presented at ECCO adds to the growing body of evidence supporting early proactive drug optimization for increased durability of infliximab. This study observed 95% sustained IFX response for CD patients after 1 year and 87% after 2 years. Read it here: https://lnkd.in/gp8CuU3x #ECCO25 #ECCO2025 #Gastroenterology #IBD #GI #GIHealth

If you’re in the Seattle area, come visit with our local Regional Technical Specialist, Nikki Bauer, on Saturday, March 8 at the IBDHorizons Pacific Northwest Symposium! She’d love to talk with you about our latest innovations in precision-guided dosing and therapy selection. #IBDHorizons25 #IBDHorizons #IBD #Gastroenterology #GI #GIHealth

Did you know? | Lifetime treatment costs for IBD are about 10 times higher than lifetime treatment costs for type 2 diabetes and heart disease. Individualized treatment plans using precision-guided dosing can help mitigate some of these costs. Learn more at prometheuslabs.com. #Gastroenterology #IBD #GI #GIHealth

In a cohort of pregnant women, diagnosed with CD and treated with RZB throughout pregnancy (n=3), serum RZB measured with HMSA technology, was detectable in all patients and infants; however, infant blood (or equivalent infant cord blood) RZB levels were less than maternal levels at birth. #Gastroenterology #GI #GIHealth #Risankizumab #Biologics #IBD

That’s a startling number. As a provider, don’t you wish there was a way to predict before initiating therapy which patients may not respond? Soon, you’ll be able to with Respondr! #Gastroenterology #IBD #GI #GIHealth

Today, we unveiled new data on precision-guided care for IBD at ECCO’25 Congress! Read the announcement and access the seven abstracts resulting from collaborations between our Research and Development team and major IBD centers of excellence in the US and Europe: https://lnkd.in/gf9BXBwR #ECCO25 #ECCO2025 #Gastroenterology #IBD #GI #GIHealth

PredictrPK is the only test for IBD patients on a biologic therapy that reports and incorporates patient drug clearance into pharmacokinetic modeling. That’s why it’s the only test on the market that truly enables precision-guided dosing to help you get your patients on the right dose at the right interval and supports improved time to remission. https://lnkd.in/e3ZCn5EZ #Gastroenterology #IBD #GI #GIHealth

Thank you to everyone who came by at #CCCongress25 to discuss how utilizing optimized therapy selection with Respondr (available soon) and precision-guided dosing with PredictrPK can improve anti-TNF drug persistence and patient outcomes. We’ll see you next year! #CrohnsColitisFoundation #Gastroenterology #IBD #GI #GIHealth

In case you missed it, at #AIBD2024, we presented the Impact of Precision-Guided Dosing on Clinical Decision Making and Health Care Utilization in IBD: 24-Month Real-World Outcome Comparison Before and After Test Implementation. Download or Zoom in to check it out. #Gastroenterology #IBD #GI #GIHealth #CCCongress25 #CrohnsColitisFoundation